<DOC>
	<DOCNO>NCT01033929</DOCNO>
	<brief_summary>The primary objective ass safety two dos C-Tb ( 0.01 0.1 µg/0.1 mL ) administer intradermally Mantoux technique patient acute phase treatment active TB . The secondary objective assess immune response two dos ( 0.01 0.1 µg/0.1 mL ) C-Tb size induration ass safety unpreserved C-Tb C-Tb preserve 0.5 % phenol ( local reaction ) .</brief_summary>
	<brief_title>A Safety Dose Finding Trial C-Tb , When Given Adult Patients Recently Diagnosed With Active Tuberculosis</brief_title>
	<detailed_description>This clinical trial single centre phase Ib open dose adjustment study respect dose C-Tb combine double blind randomise , split-body comparison unpreserved C-Tb C-Tb preserve 0.5 % phenol ( patient receive unpreserved version one arm preserve version arm ) .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>The patient : 1 . Has sign inform consent 2 . Is willing likely comply trial procedure 3 . Has diagnose active TB treatment ≤ 60 day time inclusion 1 document positive sputum smear microscopy result positive culture positive PCR result tuberculosis compatible clinical picture TB intention treat 4 . Has positive Tspot assay QuantiFERON®TB Gold In Tube test 5 . Is prepared grant authorize person access medical record The patient : 1 . Has treatment product likely modify immune response within 3 month prior day inclusion ( e.g. , immunoglobulin , systemic corticosteroid , methotrexate , azathioprine , cyclosporine blood product ) 2 . Has vaccinate live vaccine within 6 week prior day inclusion ( e.g . BCG , MMR , yellow fever , oral typhoid vaccine ) 3 . Has know congenital acquire immune deficiency 4 . Has disease affect lymphoid organ ( e.g. , Hodgkin 's disease , lymphoma , leukaemia , sarcoidosis ) 5 . Is infected HIV 6 . Has severe scarring , burn , rash , eczema , psoriasis , skin disease near injection sit 7 . Has condition blood drawing pose minimal risk patient , haemophilia , coagulation disorder , significantly impaired venous access 8 . Is actively participate another clinical trial 9 . Is pregnant accord urine pregnancy test inclusion 10 . Has condition opinion investigator suitable participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>ESAT-6</keyword>
	<keyword>CFP-10</keyword>
	<keyword>skin test</keyword>
	<keyword>diagnostic test</keyword>
</DOC>